During sedation, new standards from the Joint Commission on Accreditation of Healthcare
Organizations (JCAHO), the American Society of Anesthesiologists and the American Heart
Association, all call for monitoring ventilation such as with capnography, which is the continuous and
non-invasive measurement of carbon dioxide in exhaled human breath.
Oridion's Smart CapnoLine O2 allows physicians to comply with these standards. It collects breath
samples for CO2 analysis from both nose and mouth, while also supplying oxygen to the patient, using
one compact ergonomic nosepiece, molded from exceptionally soft and lightweight plastic. The device
is equipped with Oridion's proprietary uni-junction, a single meeting point for nose and mouth breath
sample sources. The uni-junction automatically identifies and selects the nose or mouth breath source
providing the highest-pressure sample for a smooth gas flow, then carries the sample back to the
monitor for displaying an uninterrupted waveform during sedation.
John H. Eichhorn, M.D., Professor and Chairman, Department of Anesthesiology at the University of
Mississippi Medical Center said, "This new technology, for the first time, allows continuous and
meaningful capnography in sedated patients."
Oridion Capnography Inc. is a subsidiary of Oridion Systems Ltd. and operates through its wholly
owned subsidiaries in the United States, Europe, Asia Pacific and Israel.
Oridion Systems Ltd. (ORIDN on SWX New Market), announced that it has received 510(k) clearance
from the U.S. Food and Drug Administration (FDA) for a monitoring device for non-intubated patients, the
Smart CapnoLine O2, that measures carbon dioxide samples of exhaled air with unprecedented
accuracy. This next generation capnography device helps to alert careproviders, to the earliest
possible warning signs of potentially fatal adverse events that can develop during procedural sedation.